Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing

Helen MacDonald

๐Ÿ‘ค Speaker
See mentions of this person in podcasts
1132 total appearances

Appearances Over Time

Podcast Appearances

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

And also finding something quite interesting that perhaps there was less of a benefit for women.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

So here is our verdict or their verdict.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

They make weak recommendations and suggest that there is limited evidence to suggest screening is worth it if you have less than a 3% risk of colorectal cancer over the next 10 years.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

And there is a handy online tool where you can go and work out what your risk of colorectal cancer is.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

If all of the testing options are available to you in your healthcare system, there are lots of different pros and cons of them.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

And mostly it's the practical issues or the convenience of those tests that's likely to drive your decision rather than there being a standout winner amongst those tests.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

And overall, the guidance suggests that there's really an increased need for shared decision making and discussion about what people's preferences are as to whether it's worth it.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

So they're 3% risk, are they?

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Well, that's very interesting, because one of the things that the team highlight as an uncertainty at the end of the paper was a lack of information about what the public actually viewed as a reasonable threshold to offer screening.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Well, I think this...

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

The team decided to go against an age-based approach because there are people either side of those ages that can have differing risks.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Or I guess you could use this to up the risk.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

I mean, if you wanted to identify a higher risk population and derive a bigger benefit, you could, couldn't you?

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

It was one of the most challenging ones.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Yeah, actually, if you are going to use this with a patient, what I would suggest that you do is click through onto the Magic site, which is linked from the article.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Because there you can type in your individual risk and you can pick the outcomes and results.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

conveniences that matter to you and pull it together in a very personalized way.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

On our site and in our infographic, I think it was extremely challenging to present a summary.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

So we're very aware of the fact that the graphic for this one is really only giving you the very tip of the iceberg of what data is behind that and what you can do with it.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Basically, should you scan very pregnant ladies?